Biomarker‐Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union
Clinical Pharmacology & Therapeutics · 2023-08 · 114 (2) · 316-324
DOI: 10.1002/cpt.2928 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.05.2023. Verfasst von Ciska Verbaanderd und 11 weiteren Autor:innen. Beteiligte Einrichtung: PhaRA Consulting, Antwerp, Belgium. Hauptthemen laut MEDLINE: Precision Medicine. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The new In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) introduces important changes in the EU legal framework for companion diagnostics (CDx), including a new risk‐based classification system for in vitro diagnostic tests (IVDs), a first legal definition for CDx and enhanced involvement of notified bodies in the conformity assessment and certification process of CDx. The IVDR also establishes an important link between the assessment of a CDx and the corresponding medicinal product by requiring the notified body to seek a scientific opinion from the medicines regulator on the suitability of the CDx for use with the concerned medicinal product(s) before issuing an IVD certificate. Whereas the IVDR aims at establishing a robust regulatory framework for IVDs, it is also associated with several challenges, such as insufficient capacity of notified bodies and readiness of manufacturers. To ensure timely access for patients to essential IVDs, a progressive roll‐out for this new legislation has been introduced. In addition, the new consultation process for CDx requires increased collaboration and alignment of assessments performed by the different stakeholders involved in this process. The European Medicines Agency (EMA) and notified bodies are currently building experience based on the first CDx consultation procedures that have been submitted from January 2022 onward. In the current article, we describe the new European regulatory framework for certification of CDx and highlight several challenges for medicine and CDx co‐development. In addition, we briefly touch upon the interplay between the Clinical Trial Regulation (EU) No. 536/2014 (CTR) and the IVDR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PhaRA Consulting, Antwerp, Belgium.
- European Medicines Agency, Amsterdam, The Netherlands.
- Paul Ehrlich Institute, Langen, Germany.
- Austrian Agency for Health and Food Safety, Wien, Austria.
- Spanish Agency for Medicines and Health Care Products, Madrid, Spain.
ORCID-Profile: Ciska Verbaanderd
Zitieren
APA
Verbaanderd, C., Trullás Jimeno, A., Engelbergs, J., Zander, H., Reischl, I., Moreno Oliver, A., Vamvakas, S., Vleminckx, C., Bouygues, C., Girard, T., Day, F., & Frias, Z. (2023). Biomarker‐Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union. Clinical Pharmacology & Therapeutics, 114(2), 316-324. https://doi.org/10.1002/cpt.2928
Vancouver
Verbaanderd C, Trullás Jimeno A, Engelbergs J, Zander H, Reischl I, Moreno Oliver A, et al. Biomarker‐Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union. Clinical Pharmacology & Therapeutics. 2023;114(2):316-324. doi:10.1002/cpt.2928
BibTeX
@article{Verbaanderd2023,
author = {Verbaanderd, Ciska and Trullás Jimeno, Ana and Engelbergs, Jörg and Zander, Hilke and Reischl, Ilona and Moreno Oliver, Ana and Vamvakas, Spiros and Vleminckx, Camille and Bouygues, Christelle and Girard, Thomas and Day, Francesca and Frias, Zaide},
title = {Biomarker‐Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {2},
pages = {316--324},
doi = {10.1002/cpt.2928}
}
EUVIMED